da Silva Pedro Marques, Aguiar Carlos, Morais João
Centro Hospitalar de Lisboa Central, EPE, Hospital de Santa Marta, Arterial Investigation Unit, Lisboa, Portugal.
Centro Hospitalar de Lisboa Ocidental, EPE, Hospital de Santa Cruz, Department of Cardiology, Lisboa, Portugal.
Rev Port Cardiol (Engl Ed). 2019 Aug;38(8):559-569. doi: 10.1016/j.repc.2019.02.009. Epub 2019 Nov 7.
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in Portugal. Hypercholesterolemia has a causal role in atherosclerotic CVD. Guidelines recommend that cardiovascular (CV) risk reduction should be individualized and treatment goals identified. Low-density lipoprotein cholesterol (LDL-C) is the primary treatment target.
DISGEN-LIPID was a cross-sectional observational study conducted in 24 centers in Portugal in dyslipidemic patients aged ≥40 years, on lipid-lowering therapy (LLT) for at least three months and with an available lipid profile in the previous six months.
A total of 368 patients were analyzed: 48.9% men and 51.1% women (93.9% postmenopausal), of whom 73% had a SCORE of high or very high CV risk. One quarter had a family history of premature CVD; 31% had diabetes; 26% coronary heart disease; 9.5% cerebrovascular disease; and 4.1% peripheral arterial disease. Mean baseline lipid values were total cholesterol (TC) 189 mg/dl, LDL-C 116 mg/dl, high-density lipoprotein cholesterol (HDL-C) 53.5 mg/dl, and triglycerides (TG) 135 mg/dl. Women had higher TC (p<0.001), LDL-C (non-significant) and HDL-C (p<0.001), and lower TG (p=0.002); 57% of men and 63% of women had LDL-C>100 mg/dl (p=0.28), and 58% of men and 47% of women had LDL-C>70 mg/dl (p=0.933).
These observational data show that, despite their high-risk profile, more than half of patients under LLT, both men and women, did not achieve the recommended target levels for LDL-C, and a large proportion also had abnormal HDL-C and/or TG. This is a renewed opportunity to improve clinical practice in CV prevention.
心血管疾病(CVD)是葡萄牙发病和死亡的主要原因。高胆固醇血症在动脉粥样硬化性心血管疾病中起因果作用。指南建议,心血管(CV)风险降低应个体化并确定治疗目标。低密度脂蛋白胆固醇(LDL-C)是主要治疗靶点。
DISGEN-LIPID是一项横断面观察性研究,在葡萄牙的24个中心对年龄≥40岁的血脂异常患者进行,这些患者接受降脂治疗(LLT)至少三个月,且在过去六个月内有可用的血脂谱。
共分析了368例患者:男性占48.9%,女性占51.1%(93.9%为绝经后女性),其中73%的患者心血管风险评分为高或极高。四分之一的患者有早发性心血管疾病家族史;31%患有糖尿病;26%患有冠心病;9.5%患有脑血管疾病;4.1%患有外周动脉疾病。平均基线血脂值为总胆固醇(TC)189mg/dl、低密度脂蛋白胆固醇(LDL-C)116mg/dl、高密度脂蛋白胆固醇(HDL-C)53.5mg/dl和甘油三酯(TG)135mg/dl。女性的总胆固醇(p<0.001)、低密度脂蛋白胆固醇(无显著性差异)和高密度脂蛋白胆固醇(p<0.001)较高,甘油三酯较低(p = 0.002);57%的男性和63%的女性低密度脂蛋白胆固醇>100mg/dl(p = 0.28),58%的男性和47%的女性低密度脂蛋白胆固醇>70mg/dl(p = 0.933)。
这些观察数据表明,尽管接受降脂治疗的患者具有高风险特征,但超过一半的患者,无论男性还是女性,均未达到低密度脂蛋白胆固醇的推荐目标水平,并且很大一部分患者的高密度脂蛋白胆固醇和/或甘油三酯也异常。这是改善心血管预防临床实践的新契机。